XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.23.2

Balance Sheet Details | 6 Months Ended
--- | ---
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Details | 2. Balance Sheet Details Property, Plant and Equipment, net Property, plant and equipment, net, consist of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
Computer equipment and software |  | $ | 1,090 |  |  | $ | 1,078 |
Furniture and fixtures |  |  | 1,089 |  |  |  | 1,086 |
Leasehold improvements |  |  | 115 |  |  |  | 115 |
Construction in process |  |  | 604 |  |  |  | 399 |
Total property, plant and equipment, gross |  |  | 2,898 |  |  |  | 2,678 |
Less: accumulated depreciation |  |  | (1,740 | ) |  |  | (1,471 | )
Total property, plant and equipment, net |  | $ | 1,158 |  |  | $ | 1,207 |
Depreciation expense for each of the three months ended June 30, 2023 and 2022 was approximately $0.1 million. Depreciation expense for each of the six months ended June 30, 2023 and 2022 was approximately $0.3 million. No property, plant or equipment was disposed of during the six months ended June 30, 2023 or the year ended December 31, 2022. Accrued Expenses Accrued expenses consist of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
Accrued research and development expenses |  | $ | 6,716 |  |  | $ | 3,080 |
Accrued compensation expenses |  |  | 6,531 |  |  |  | 8,447 |
Accrued professional & consulting expenses |  |  | 2,183 |  |  |  | 3,000 |
Accrued other |  |  | 21 |  |  |  | 151 |
Total accrued expenses |  | $ | 15,451 |  |  | $ | 14,678 |
Inventory Inventory consist of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
Raw materials |  | $ | 111 |  |  | $ | — |
Total inventory, current |  | $ | 111 |  |  | $ | — |
Raw materials, noncurrent |  |  | 3,450 |  |  |  | — |
Total inventory |  | $ | 3,561 |  |  | $ | — |
Raw materials consist of materials, including active pharmaceutical ingredients, to be consumed in the production of inventory related to the FDA approved products. $3.5 million of raw materials are included within other long-term assets as of June 30, 2023.

X
- Definition Component of Balance Sheet Disclosure. + References No definition available. + Details
Name: | phat_ComponentOfBalanceSheetDisclosureTextBlock
Namespace Prefix: | phat_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration